{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T15:36:15Z","timestamp":1778081775197,"version":"3.51.4"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K23AR073931"],"award-info":[{"award-number":["K23AR073931"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30AR072583"],"award-info":[{"award-number":["P30AR072583"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Patients with RA are at an increased risk for serious infections, but less is known about more common, non-serious infections. We aimed to assess the frequency and characteristics of non-serious infections and their effect on medication interruptions, quality of life, and disease flares.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We remotely recruited adults with RA from July 2022 to July 2023 through a community rheumatology practice\u2013based research network. Participants joined the ArthritisPower Registry (now PatientSpot) and completed a baseline survey and up to six monthly follow-up surveys, focused on patient-reported outcomes (PROs), infections, medication interruptions, and disease flares. The impact of infections was evaluated by comparing survey measures in those with vs without an infection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We recruited 351 patients with RA who contributed 1674 monthly observations. Patients reported 523 infections (31% of observations), most frequently upper respiratory infections. Although few infections led to emergency department visits or hospitalizations, infections frequently led to missed work (37%) or RA treatment interruptions (26%). RA treatment interruptions were more common in those with vs without health-care encounters or antibiotic use (38% vs 12%) and in more severe vs less severe infections (47% vs 20%). Infections were associated with worse scores for fatigue but not function, depression, or social participation. Frequency of disease flares was greater in those with an infection who interrupted RA treatment, especially in patients receiving tumor necrosis factor (TNF) inhibitors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Infections are common in patients with RA and frequently lead to medication interruptions. These infections are associated with greater fatigue and impaired work productivity and may contribute to more disease flares.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaf503","type":"journal-article","created":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T11:53:25Z","timestamp":1758196405000},"source":"Crossref","is-referenced-by-count":1,"title":["Impact of non-serious infections on medication interruptions, quality of life, and disease flares in patients with rheumatoid arthritis"],"prefix":"10.1093","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-2256-9586","authenticated-orcid":false,"given":"Heta","family":"Patel","sequence":"first","affiliation":[{"name":"Perelman School of Medicine, University of Pennsylvania , Philadelphia, PA,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2615-4940","authenticated-orcid":false,"given":"Kelly","family":"Gavigan","sequence":"additional","affiliation":[{"name":"Global Healthy Living Foundation , New York, NY,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3889-9034","authenticated-orcid":false,"given":"Shilpa","family":"Venkatachalam","sequence":"additional","affiliation":[{"name":"Global Healthy Living Foundation , New York, NY,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Curtis","sequence":"additional","affiliation":[{"name":"Global Healthy Living Foundation , New York, NY,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6890-1022","authenticated-orcid":false,"given":"Laura","family":"Stradford","sequence":"additional","affiliation":[{"name":"Global Healthy Living Foundation , New York, NY,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4951-6476","authenticated-orcid":false,"given":"W Benjamin","family":"Nowell","sequence":"additional","affiliation":[{"name":"Global Healthy Living Foundation , New York, NY,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0799-7563","authenticated-orcid":false,"given":"Joshua F","family":"Baker","sequence":"additional","affiliation":[{"name":"Perelman School of Medicine, University of Pennsylvania , Philadelphia, PA,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fenglong","family":"Xie","sequence":"additional","affiliation":[{"name":"Foundation for Advancing Science, Technology, Education and Research , Birmingham, AL,","place":["USA"]},{"name":"Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham , Birmingham, AL,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8907-8976","authenticated-orcid":false,"given":"Jeffrey R","family":"Curtis","sequence":"additional","affiliation":[{"name":"Foundation for Advancing Science, Technology, Education and Research , Birmingham, AL,","place":["USA"]},{"name":"Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham , Birmingham, AL,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0398-2308","authenticated-orcid":false,"given":"Michael D","family":"George","sequence":"additional","affiliation":[{"name":"Perelman School of Medicine, University of Pennsylvania , Philadelphia, PA,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,9,19]]},"reference":[{"key":"2026020205381816400_keaf503-B1","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1002\/acr.20105","article-title":"Excess mortality emerges after 10 years in an inception cohort of early rheumatoid arthritis","volume":"62","author":"Radovits","year":"2010","journal-title":"Arthritis Care Res"},{"key":"2026020205381816400_keaf503-B2","first-page":"S35","article-title":"Mortality in rheumatoid arthritis: 2008 update","volume":"26","author":"Sokka","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"2026020205381816400_keaf503-B3","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s00296-016-3638-5","article-title":"Mortality in patients with rheumatoid arthritis: a 15-year prospective cohort study","volume":"37","author":"van den Hoek","year":"2017","journal-title":"Rheumatol Int"},{"key":"2026020205381816400_keaf503-B4","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1093\/rheumatology\/kew502","article-title":"Cause-specific mortality in patients with psoriatic arthritis and rheumatoid arthritis","volume":"56","author":"Ogdie","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"2026020205381816400_keaf503-B5","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1002\/acr.25053","article-title":"A narrowing mortality gap: temporal trends of cause-specific mortality in a national matched cohort study in US veterans with rheumatoid arthritis","volume":"75","author":"Johnson","year":"2023","journal-title":"Arthritis Care Res"},{"key":"2026020205381816400_keaf503-B6","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1002\/art.21386","article-title":"Infections in patients with rheumatoid arthritis treated with biologic agents","volume":"52","author":"Listing","year":"2005","journal-title":"Arthritis Rheum"},{"key":"2026020205381816400_keaf503-B7","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1002\/art.23913","article-title":"Use of nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis","volume":"59","author":"Lacaille","year":"2008","journal-title":"Arthritis Rheum"},{"key":"2026020205381816400_keaf503-B8","doi-asserted-by":"crossref","first-page":"e0296821","DOI":"10.1371\/journal.pone.0296821","article-title":"Burden of non-serious infections during biological use for rheumatoid arthritis","volume":"19","author":"Bergmans","year":"2024","journal-title":"PLoS One"},{"key":"2026020205381816400_keaf503-B9","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1056\/NEJMoa1608345","article-title":"Baricitinib versus placebo or adalimumab in rheumatoid arthritis","volume":"376","author":"Taylor","year":"2017","journal-title":"N Engl J Med"},{"key":"2026020205381816400_keaf503-B10","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1136\/annrheumdis-2011-200706","article-title":"Safety and efficacy of ocrelizumab in combination with methotrexate in MTX-naive subjects with rheumatoid arthritis: the phase III FILM trial","volume":"71","author":"Stohl","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"2026020205381816400_keaf503-B11","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1136\/ard.2008.099218","article-title":"The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial","volume":"68","author":"Schiff","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2026020205381816400_keaf503-B12","doi-asserted-by":"crossref","first-page":"3432","DOI":"10.1002\/art.20568","article-title":"Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial","volume":"50","author":"St Clair","year":"2004","journal-title":"Arthritis Rheum"},{"key":"2026020205381816400_keaf503-B13","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1378\/chest.122.2.603","article-title":"Economic burden of respiratory infections in an employed population","volume":"122","author":"Birnbaum","year":"2002","journal-title":"Chest"},{"key":"2026020205381816400_keaf503-B14","doi-asserted-by":"crossref","first-page":"112","DOI":"10.4193\/Rhin19.424","article-title":"The socioeconomic cost of chronic rhinosinusitis study","volume":"58","author":"Wahid","year":"2020","journal-title":"Rhinology"},{"key":"2026020205381816400_keaf503-B15","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1001\/archinte.163.4.487","article-title":"The economic burden of non\u2013influenza-related viral respiratory tract infection in the United States","volume":"163","author":"Fendrick","year":"2003","journal-title":"Arch Intern Med"},{"key":"2026020205381816400_keaf503-B16","doi-asserted-by":"crossref","first-page":"603","DOI":"10.3899\/jrheum.201017","article-title":"Concerns, healthcare use, and treatment interruptions in patients with common autoimmune rheumatic diseases during the COVID-19 pandemic","volume":"48","author":"George","year":"2021","journal-title":"J Rheumatol"},{"key":"2026020205381816400_keaf503-B17","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.rdc.2012.08.016","article-title":"Nonserious infections: should there by cause for serious concerns?","volume":"38","author":"Dao","year":"2012","journal-title":"Rheum Dis Clin North Am"},{"key":"2026020205381816400_keaf503-B18","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/art.24463","article-title":"Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis","volume":"61","author":"Du Pan","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2026020205381816400_keaf503-B19","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/acr.24837","article-title":"Medication interruptions and subsequent disease flares during the COVID-19 pandemic: a longitudinal online study of patients with rheumatic disease","volume":"74","author":"Dharia","year":"2022","journal-title":"Arthritis Care Res"},{"key":"2026020205381816400_keaf503-B20","doi-asserted-by":"crossref","first-page":"152025","DOI":"10.1016\/j.semarthrit.2022.152025","article-title":"DMARD disruption, rheumatic disease flare, and prolonged COVID-19 symptom duration after acute COVID-19 among patients with rheumatic disease: a prospective study","volume":"55","author":"Di Iorio","year":"2022","journal-title":"Semin Arthritis Rheum"},{"key":"2026020205381816400_keaf503-B21","doi-asserted-by":"crossref","first-page":"e70067","DOI":"10.1002\/pds.70067","article-title":"Generating real-world evidence from the excellence network in rheumatology","volume":"33","author":"Beukelman","year":"2024","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2026020205381816400_keaf503-B22","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","article-title":"The validity and reproducibility of a work productivity and activity impairment instrument","volume":"4","author":"Reilly","year":"1993","journal-title":"Pharmacoeconomics"},{"key":"2026020205381816400_keaf503-B23","doi-asserted-by":"crossref","first-page":"719","DOI":"10.7326\/0003-4819-53-4-719","article-title":"Susceptibility and immunity to common upper respiratory viral infections\u2014the common cold","volume":"53","author":"Jackson","year":"1960","journal-title":"Ann Intern Med"},{"key":"2026020205381816400_keaf503-B24","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1136\/ard.2010.144741","article-title":"The influence of systemic glucocorticoid therapy upon the risk of non-serious infection in older patients with rheumatoid arthritis: a nested case\u2013control study","volume":"70","author":"Dixon","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2026020205381816400_keaf503-B25","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1002\/art.41754","article-title":"Nonserious infections in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis","volume":"73","author":"Bechman","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2026020205381816400_keaf503-B26","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1136\/ard.2010.128637","article-title":"High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis","volume":"70","author":"Au","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2026020205381816400_keaf503-B27","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1002\/art.21568","article-title":"Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti\u2013tumor necrosis factor therapy","volume":"54","author":"Wolfe","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2026020205381816400_keaf503-B28","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S0140-6736(14)61704-9","article-title":"Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis","volume":"386","author":"Singh","year":"2015","journal-title":"Lancet"},{"key":"2026020205381816400_keaf503-B29","doi-asserted-by":"crossref","first-page":"e000935","DOI":"10.1136\/rmdopen-2019-000935","article-title":"Serious infection risk in rheumatoid arthritis compared with non-inflammatory rheumatic and musculoskeletal diseases: a US national cohort study","volume":"5","author":"Mehta","year":"2019","journal-title":"RMD Open"},{"key":"2026020205381816400_keaf503-B30","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1136\/annrheumdis-2017-212825","article-title":"Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis","volume":"77","author":"Rutherford","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2026020205381816400_keaf503-B31","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.apmr.2015.09.022","article-title":"Effects of person-centered physical therapy on fatigue-related variables in persons with rheumatoid arthritis: a randomized controlled trial","volume":"97","author":"Feldthusen","year":"2016","journal-title":"Arch Phys Med Rehabil"},{"key":"2026020205381816400_keaf503-B32","doi-asserted-by":"crossref","first-page":"591","DOI":"10.3390\/clinpract12040062","article-title":"The assessment of fatigue in rheumatoid arthritis patients and its impact on their quality of life","volume":"12","author":"Dar","year":"2022","journal-title":"Clin Pract"},{"key":"2026020205381816400_keaf503-B33","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1093\/rheumatology\/key208","article-title":"The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis","volume":"58","author":"Holroyd","year":"2019","journal-title":"Rheumatology (Oxford)"},{"key":"2026020205381816400_keaf503-B34","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/s13075-020-02257-1","article-title":"Temporary interruption of baricitinib: characterization of interruptions and effect on clinical outcomes in patients with rheumatoid arthritis","volume":"22","author":"Emery","year":"2020","journal-title":"Arthritis Res Ther"},{"key":"2026020205381816400_keaf503-B35","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1080\/08916934.2022.2067985","article-title":"Short interruptions of TNF-inhibitor treatment can be associated with treatment failure in patients with immune-mediated diseases","volume":"55","author":"Lamberg","year":"2022","journal-title":"Autoimmunity"},{"key":"2026020205381816400_keaf503-B36","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.cgh.2006.06.025","article-title":"Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn\u2019s disease","volume":"4","author":"Maser","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026020205381816400_keaf503-B37","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1136\/gut.2006.099978","article-title":"Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn\u2019s disease","volume":"56","author":"Vermeire","year":"2007","journal-title":"Gut"},{"key":"2026020205381816400_keaf503-B38","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/j.1365-2036.2011.04612.x","article-title":"Review article: loss of response to anti-TNF treatments in Crohn\u2019s disease","volume":"33","author":"Ben-Horin","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"2026020205381816400_keaf503-B39","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/ajg.2016.54","article-title":"The risk of relapse after anti-TNF discontinuation in inflammatory bowel disease: systematic review and meta-analysis","volume":"111","author":"Gisbert","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"2026020205381816400_keaf503-B40","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.clinthera.2017.03.005","article-title":"Clinical outcomes associated with switching or discontinuation from anti-TNF inhibitors for nonmedical reasons","volume":"39","author":"Wolf","year":"2017","journal-title":"Clin Ther"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keaf503\/64325408\/keaf503.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/65\/1\/keaf503\/64325408\/keaf503.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/65\/1\/keaf503\/64325408\/keaf503.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T10:38:28Z","timestamp":1770028708000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/doi\/10.1093\/rheumatology\/keaf503\/8258624"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,19]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,8]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaf503","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2025,9,19]]},"article-number":"keaf503"}}